Efficacy and safety of desensitization with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients infected with human immunodeficiency virus.
OBJECTIVE
To study the safety and efficacy of desensitization with the use of a combination product of sulfamethoxazole and trimethoprim in previously hypersensitive patients infected with the human immunodeficiency virus.


METHODS
Prospective survey, with a median follow-up of 16 months (range, 5-24 months).


METHODS
Day-care hospital in a referral center.


METHODS
All human immunodeficiency virus-infected patients who had a history of allergic reactions (eg, rash) to sulfamethoxazole-trimethoprim and who required sulfamethoxazole-trimethoprim prophylaxis.


METHODS
The desensitization procedure took 2 days. The full dose (sulfamethoxazole-trimethoprim, 400-80 mg) was reached on the third day according to the following schedule: day 1--4-0.8 mg at 9 AM, 8-1.6 mg at 11 AM, 20-4 mg at 1 PM, and 40-8 mg at 5 PM; day 2--80-16 mg at 9 AM, 160-32 mg at 3 PM, and 200-40 mg at 9 PM; and day 3--400-80 mg at 9 AM.


METHODS
The onset of cutaneous adverse effects attributable to sulfamethoxazole-trimethoprim therapy within 3 months after desensitization.


RESULTS
Of the 48 evaluable patients, 37 (77%) tolerated sulfamethoxazole-trimethoprim desensitization without toxic effects and continued to take sulfamethoxazole-trimethoprim daily. Desensitization failed in 11 cases (5 on day 1, 3 on day 2, and 1 each on days 9, 11, and 90). Acute hypotension and a nonfatal myocardial infarction developed in 1 of these patients. The factors that were predictive of failure were a relatively high CD4+ cell percentage (11% vs 8%; P = .008) and a relatively high CD4+/CD8+ ratio (0.27 vs 0.12; P = .02).


CONCLUSIONS
The efficacy of desensitization with sulfamethoxazole-trimethoprim was confirmed; this desensitization procedure was more often successful in patients with lower CD4+ cell percentages and CD4+/CD8+ ratios. However, sulfamethoxazole-trimethoprim therapy should be reintroduced carefully.
Caumes
E
E
Service des Maladies Infectieuses et Tropicales, Hôpital Pitié-Salpêtrière, Paris, France.
Guermonprez
G
G
Lecomte
C
C
Katlama
C
C
Bricaire
F
F
D000328:Adult; D000890:Anti-Infective Agents / Q000276:immunology / Q000627:therapeutic use*; D003888:Desensitization, Immunologic; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000209:etiology / Q000628:therapy*; D004342:Drug Hypersensitivity / Q000209:etiology / Q000628:therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013420:Sulfamethoxazole / Q000276:immunology / Q000627:therapeutic use*; D014295:Trimethoprim / Q000276:immunology / Q000627:therapeutic use*
D000890:Anti-Infective Agents; D014295:Trimethoprim; D013420:Sulfamethoxazole